Thyroid Head and Neck Ablation Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan
Search for other papers by Pi-Ling Chiang in
Google Scholar
PubMed
Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Search for other papers by Sheng-Dean Luo in
Google Scholar
PubMed
Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Search for other papers by Yen-Hsiang Chang in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Search for other papers by Chen-Kai Chou in
Google Scholar
PubMed
Departments of Surgery, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Search for other papers by Shun-Yu Chi in
Google Scholar
PubMed
Thyroid Head and Neck Ablation Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan
Search for other papers by Yi-Fan Chen in
Google Scholar
PubMed
Thyroid Head and Neck Ablation Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan
Department of Radiology, Jen-Ai Hospital, Dali Branch, Taichung, Taiwan
School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung City, Taiwan
Search for other papers by Wei-Che Lin in
Google Scholar
PubMed
/FLUS) category, known as Bethesda category III, has been ascribed a malignancy risk of 5–15% ( 2 , 3 , 4 , 5 ). According to international guidelines, Bethesda III thyroid nodules are not considered an indication of radiofrequency ablation (RFA) ( 6 , 7
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Search for other papers by Maurilio Deandrea in
Google Scholar
PubMed
Search for other papers by Stefano Borgato in
Google Scholar
PubMed
Search for other papers by Marco Dell’Acqua in
Google Scholar
PubMed
Search for other papers by Francesca Retta in
Google Scholar
PubMed
Search for other papers by Alberto Mormile in
Google Scholar
PubMed
Search for other papers by Chiara Carzaniga in
Google Scholar
PubMed
Search for other papers by Giacomo Gazzano in
Google Scholar
PubMed
Search for other papers by Gabriele Pogliaghi in
Google Scholar
PubMed
Search for other papers by Marina Muzza in
Google Scholar
PubMed
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
treatment in advanced and infiltrative thyroid tumors ( 4 ). No specific recommendations are available regarding the use of RFA or other mini-invasive procedures in indeterminate nodules (Bethesda III and IV). According to the last Bethesda classification
Search for other papers by Maria Mavromati in
Google Scholar
PubMed
Search for other papers by Essia Saiji in
Google Scholar
PubMed
Search for other papers by Marco Stefano Demarchi in
Google Scholar
PubMed
Search for other papers by Vincent Lenoir in
Google Scholar
PubMed
Search for other papers by Amanda Seipel in
Google Scholar
PubMed
Search for other papers by Paulina Kuczma in
Google Scholar
PubMed
Search for other papers by François R Jornayvaz in
Google Scholar
PubMed
Search for other papers by Minerva Becker in
Google Scholar
PubMed
Search for other papers by Eugenio Fernandez in
Google Scholar
PubMed
Search for other papers by Claudio De Vito in
Google Scholar
PubMed
Search for other papers by Frédéric Triponez in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
, ultrasound scores are used to determine which nodules should undergo FNAC and the Bethesda classification is used to assess management based on the risk of malignancy ( 7 , 8 ). Suspicious nodules with Bethesda III, Bethesda IV, and Bethesda V cytology
Department of Pathology, General University Hospital of Ciudad Real, Ciudad Real, Spain
Search for other papers by Ana Isabel Álvarez-Mancha in
Google Scholar
PubMed
Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Málaga, Spain
Search for other papers by Isabel Mancha-Doblas in
Google Scholar
PubMed
The Biomedical Research Institute of Malaga and Platform in Nanomedicine (IBIMA-BIONAND Platform), University of Malaga, Malaga, Spain
Search for other papers by María Molina-Vega in
Google Scholar
PubMed
Search for other papers by Diego Fernández-García in
Google Scholar
PubMed
The Biomedical Research Institute of Malaga and Platform in Nanomedicine (IBIMA-BIONAND Platform), University of Malaga, Malaga, Spain
Search for other papers by Ana María Gómez-Pérez in
Google Scholar
PubMed
Department of Pathology, Virgen de la Victoria University Hospital, Málaga, Spain
Search for other papers by Elena Gallego-Domínguez in
Google Scholar
PubMed
Department of Pathology, Virgen de la Victoria University Hospital, Málaga, Spain
Search for other papers by María Victoria Ortega-Jiménez in
Google Scholar
PubMed
Search for other papers by Isabel Hierro-Martín in
Google Scholar
PubMed
Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Málaga, Spain
The Biomedical Research Institute of Malaga and Platform in Nanomedicine (IBIMA-BIONAND Platform), University of Malaga, Malaga, Spain
Search for other papers by Francisco J Tinahones in
Google Scholar
PubMed
). Currently, the approach to Bethesda III diagnosis is determined by clinical and ultrasound risk factors ( 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ). It is generally reasonable to adopt a conservative approach with ultrasound surveillance and repeat FNA
Search for other papers by X Y Hu in
Google Scholar
PubMed
Search for other papers by J Wu in
Google Scholar
PubMed
Search for other papers by P Seal in
Google Scholar
PubMed
Department of Medicine, Section of Endocrinology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Search for other papers by S A Ghaznavi in
Google Scholar
PubMed
Search for other papers by C Symonds in
Google Scholar
PubMed
Search for other papers by S Kinnear in
Google Scholar
PubMed
Departments of Medicine, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Search for other papers by R Paschke in
Google Scholar
PubMed
indeterminate (Bethesda III/IV) nodule identified on FNA in the Calgary and Southern Alberta Healthcare region between July 31, 2020, and November 1, 2021. After excluding thyroid biopsy ultrasound reports and 2 ultrasound reports performed before 2018, there
Search for other papers by Aglaia Kyrilli in
Google Scholar
PubMed
Search for other papers by Nunzia Tacelli in
Google Scholar
PubMed
Search for other papers by Lucia Russo in
Google Scholar
PubMed
Search for other papers by Laetitia Lebrun in
Google Scholar
PubMed
Search for other papers by Isabelle Salmon in
Google Scholar
PubMed
Search for other papers by Gilles Russ in
Google Scholar
PubMed
Search for other papers by Rodrigo Moreno-Reyes in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
according to the Bethesda classification system ( 24 ). DNA was obtained from all Bethesda III, IV, and V cytological samples and was subjected to targeted next-generation sequencing using Ion Gene Studio S5, Ion Torrent Platform with AmpliSeq TM Kit (Life
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Min Ren in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Qianlan Yao in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Longlong Bao in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Zhiting Wang in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Ran Wei in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Qianming Bai in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Bo Ping in
Google Scholar
PubMed
Department of Ultrasound, Fudan University Shanghai Cancer Center, Shanghai, China
Search for other papers by Cai Chang in
Google Scholar
PubMed
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Search for other papers by Yu Wang in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Xiaoyan Zhou in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Xiaoli Zhu in
Google Scholar
PubMed
V600E-mutated FNA samples with very low allelic frequency (AF, 1–2%) were verified as truly positive using amplification refractory mutation system (ARMS) testing. In the series of 313 cytologically negative (13 Bethesda I/II) and positive (300
Search for other papers by Mohamed Abdouh in
Google Scholar
PubMed
Search for other papers by Roger Tabah in
Google Scholar
PubMed
Search for other papers by Vincenzo Arena in
Google Scholar
PubMed
Search for other papers by Manuel Arena in
Google Scholar
PubMed
Search for other papers by Zu-hua Gao in
Google Scholar
PubMed
Istituto Oncologico del Mediterraneo, Viagrande, Italy
Search for other papers by Aurelio Lorico in
Google Scholar
PubMed
Istituto Oncologico del Mediterraneo, Viagrande, Italy
Department of Surgery, McGill University, St. Mary Hospital, Montreal, Québec, Canada
Search for other papers by Goffredo Orazio Arena in
Google Scholar
PubMed
with thyroid nodules. MATER-D Test Accurately Discriminates Benign from Malignant Lesions in Bethesda III/IV Patients To verify the accuracy of the MATER-D test in the group of patients with thyroid lesions, we performed a subgroup analysis of
Search for other papers by Kassia B. Reuters in
Google Scholar
PubMed
Search for other papers by Maria C.O.C. Mamone in
Google Scholar
PubMed
Search for other papers by Elsa S. Ikejiri in
Google Scholar
PubMed
Search for other papers by Cleber P. Camacho in
Google Scholar
PubMed
Search for other papers by Claudia C.D. Nakabashi in
Google Scholar
PubMed
Search for other papers by Carolina C.P.S. Janovsky in
Google Scholar
PubMed
Search for other papers by Ji H. Yang in
Google Scholar
PubMed
Search for other papers by Danielle M. Andreoni in
Google Scholar
PubMed
Santa Casa de São Paulo, São Paulo, Brazil
Search for other papers by Rosalia Padovani in
Google Scholar
PubMed
Fleury Medicina e Saúde, São Paulo, Brazil
Search for other papers by Rui M.B. Maciel in
Google Scholar
PubMed
Search for other papers by Felipe A.B. Vanderlei in
Google Scholar
PubMed
Fleury Medicina e Saúde, São Paulo, Brazil
Search for other papers by Rosa P.M. Biscolla in
Google Scholar
PubMed
malignancy rates and approaches to treatment. These 6 categories are: nondiagnostic or unsatisfactory (ND, Bethesda I), benign (Bethesda II), atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS, Bethesda III
Search for other papers by Kristine Z Swan in
Google Scholar
PubMed
Search for other papers by Johnson Thomas in
Google Scholar
PubMed
Search for other papers by Viveque E Nielsen in
Google Scholar
PubMed
Search for other papers by Marie Louise Jespersen in
Google Scholar
PubMed
Search for other papers by Steen J Bonnema in
Google Scholar
PubMed
large study, in which ACR TIRADS misclassified 32% of malignant nodules ( 18 ). In the indeterminate categories (Bethesda III, IV, and V), NPV of TIRADS was similar to that found in the whole cohort, while NPV of AIBx decreased to 81.5%. This is